Part of the pharmaceutical government pricing was canceled

After all, drugs are not ordinary commodities. Drug prices are like minors need special treatment. We let him learn to walk and learn to be independent, but they can't completely shake hands.

Recently, the National Development and Reform Commission announced that from June 1st onwards, most government drugs will be priced out. Drug prices are mainly formed by market competition. Eliminating government pricing for pharmaceuticals means that the government will release its visible hand and play a better role in the market. This seems to be a policy full of good intentions, which has led to all sorts of questions on the street. As the people's most direct experience is that companies set their own prices, will there be a batch of drugs to raise prices? It is difficult for ordinary people to understand the cost of drug production. The pricing of the government has been liberalized. Is the price going to follow them? If it is a life-saving drug chaos how to do? Some professionals also pointed out that blindly canceling the government pricing of pharmaceutical products has had failures. The drug price control is a common practice among countries in the world.

It is not necessarily a bad thing for customers to watch drugs. The cancellation of drug pricing is not necessarily a bad thing. The reason is very simple. The government’s pricing power is handed over to the market, allowing various types of drug companies to fully compete in the market. This will not lead to price increases, and it will even bring down the return of drug prices. To the normal state. In recent years, the costs of raw materials, labor, logistics, etc. have risen, and the production costs of some cheap medicines have approached the selling prices. The winning bid companies can only afford to support the supply of raw materials while at the same time ensuring profitability even at a loss, especially with medical insurance. The implementation of the basic drug system, pharmaceutical companies for their own survival and market competition, pharmaceutical companies are reluctant to produce low-cost essential drugs, instead of producing expensive high-profit drugs. Without government pricing, more pharmaceutical companies will participate in the competition, which will promote healthy competition in the market.

Virtuous competition is an ideal state, but after all, reality is very skinny. For example, the competition in the pharmaceutical industry may be exacerbated. For the pharmaceutical industry, reforms are beneficial to powerful brand-name companies. They will become stronger and stronger, and some small enterprises that are keen on low-level repetition will become even more difficult. Be eliminated. Drugs are concentrated in the hands of a few large pharmaceutical companies, will there be a price monopoly? How to deal with vicious competition?

Is medicine price "regulating" or "releasing" good? Obviously not a simple question.

From an international point of view, in countries and regions where social health insurance systems are relatively mature and unified, market transaction prices are not directly limited, and comprehensive supervision through the strengthening of medical insurance, procurement, and price behavior has gradually become mainstream. For example, the United Kingdom manages all drug costs through a national trust (equivalent to an insurance company), and it decides which medicines can be reimbursed and how much they can reimburse. Therefore, this sector is the most active in the entire health care system in the United Kingdom. It plays a regulatory role in the pharmaceutical market. The government's decision to liberalize the price of pharmaceuticals is not the same as giving up the government's supervision of drug prices, but rather putting together the combination of "tangible hands" and "invisible hands."

It is a great pleasure to see that, while announcing the release of drug prices, the National Development and Reform Commission stated that it is necessary to increase penalties for drug price violations. In order to disrupt the market price order by taking advantage of the price reform of pharmaceuticals, in particular, the typical cases of severely aggravated special cases, such as the price of special drugs for special patients, must be severely punished according to law and effectively deter illegal operators. At the same time, a credit reward and punishment mechanism was established to include drug price violations in price credit records and so on.

Drugs are not ordinary commodities, and prices cannot be left unrestrained. All of us are aware of this. An inappropriate analogy is that the drug price is like a child needing special treatment. We let him learn to walk and learn to be independent, but I can't completely shake it off. There are many unpredictable problems and risks around.